Future generations of drugs that target PRMT5 activity in an MTAP-negative background must focus on maximising their selectivity for inhibiting PRMT5 specifically within the cancer cell (i.e. when PRMT5 is bound to MTA). This evidence concerns the gene MTAP and cancer.